Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective cohort analysis to determine the safety of Exparel as an agent for local infiltration in patients 0 to 16 years of age, based on the off-label use in Cleveland Clinic

Trial Profile

A retrospective cohort analysis to determine the safety of Exparel as an agent for local infiltration in patients 0 to 16 years of age, based on the off-label use in Cleveland Clinic

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Nov 2018 New trial record
    • 17 Oct 2018 Primary endpoint (incidence of 2 or more of the pre-defined 13 complications deemed related to local anesthetic systemic toxicity and attributable to EXPAREL or bupivacaine) has not been met as per results presented at the ANESTHESIOLOGY 2018: Annual Meeting of the American Society of Anesthesiologists
    • 17 Oct 2018 Results presented at the ANESTHESIOLOGY 2018: Annual Meeting of the American Society of Anesthesiologists
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top